Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AOTI, Inc. ( (GB:AOTI) ) has issued an announcement.
AOTI, Inc. announced a trading update for 2024, reporting expected revenues of over $58.1 million, a 32% increase from the previous year. The company has diversified its sales channels beyond the Veterans Affairs sector, leading to margin improvements and an expected increase in Adjusted EBITDA margin to 13.8%. AOTI’s strategic investments in new market channels and enhanced payer communication are anticipated to sustain high growth levels, positioning the company strongly in the high-growth sector of chronic disease management.
More about AOTI, Inc.
AOTI, Inc. is a medical technology company founded in 2006, with locations in Oceanside, California, and Galway, Ireland. The company focuses on innovative solutions to treat severe and chronic wounds, aiming to reduce healthcare costs and enhance the quality of life for patients. Its flagship product, Topical Wound Oxygen (TWO2) therapy, has been shown to significantly reduce hospitalizations and amputations related to Diabetic Foot Ulcers (DFUs). This non-invasive therapy has received regulatory approval across multiple regions, including the US, Europe, and Asia.
YTD Price Performance: 3.60%
Average Trading Volume: 68,023
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £122.3M
For an in-depth examination of AOTI stock, go to TipRanks’ Stock Analysis page.